ACTA1 and neoplasm: We also evaluated the association between amount of tumor-stromal α-SMA+ myofibroblast and patient prognosis and discovered a tendency for a similar association between the amount of tumor-stromal α-SMA+ myofibroblast and patient prognosis, with a shorter OS in patients with low amounts of tumor-stromal α-SMA+ myofibroblast compared to those with high amounts (24.7 months vs. 33.4 months, P = 0.09) (Fig. 2b).